BioSpace News Archive

HPPI’s patent portfolio expands with claims covering treatment of both hematologic and non-hematologic cancers with itraconazole, the active ingredient in HPPI’s current and anticipated future product candidates

Insulia® to be added to WellDyneRx’s WellManaged-Diabetes program

Precision BioSciences, the ARCUS genome editing company with novel product development programs in gene therapy, cancer immunotherapy and non-GMO food, will give three presentations at the upcoming ASGCT 21st Annual Meeting held in Chicago, Illinois, May 16-19, 2018.

Telescope Implant for End-Stage Macular Degeneration is FDA Approved and Available to Patients 65 Years and Older Who Have Not Had Cataract Surgery

TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today that its Chief Executive Officer, Garry E. Menzel, PhD, will present a corporate overview at the following upcoming investment conferences

Gary S. Gillheeney, Sr., President and CEO of Organogenesis Inc., has been appointed to the Massachusetts Biotechnology Council (MassBio) Board of Directors

Dr. Lee’s address on “Novel Column Technologies for Portable Capillary Chromatography” will be presented tomorrow, May 15, at the prestigious conference being held at the Congress Centre in Riva del Garda, Italy; Dr. Lee and Axcend will also spotlight the award-winning, portable Axcend Focus LC high performance liquid chromatography system (HPLC) in booth #26 during the exhibition portion of ISCC42

Coincides with global Boeing well-being initiative Includes $500,000 for veteran recovery and rehabilitation services in Australia, UK and U.S.

OMNIlife science, Inc. reported today that Rick Epstein has joined as CEO

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients two years of age and older. Actemra can be given alone or in combination with methotrexate (MTX) in patients with PJIA